Actively Recruiting
A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
Led by Li Qiang · Updated on 2025-08-27
286
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of this clinical trial is to compare the effects of yttrium-90 (SIRT) treatment and hepatic arterial perfusion chemotherapy (HAIC) on progression-free survival (PFS) in patients with potentially resectable HCC in the HCC population. The main questions it aims to answer are: * Whether yttrium-90 (SIRT) therapy is more effective than hepatic arterial infusion chemotherapy (HAIC) in treating patients with potentially resectable liver cancer * Whether yttrium-90 (SIRT) therapy is safer than hepatic arterial perfusion chemotherapy (HAIC) in patients with potentially resectable liver cancer The researchers compared yttrium-90 (SIRT) treatment to hepatic arterial perfusion chemotherapy (HAIC) to see if yttrium-90 (SIRT) was more effective in treating potentially resectable liver cancer. Participants will: * Patients will receive yttrium-90 (SIRT) therapy or 1 of them hepatic arterial perfusion chemotherapy (HAIC). * Follow-up at 1, 3, and 6 months after surgery * Keep a record of their symptoms and test results
CONDITIONS
Official Title
A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years
- Good general health with ECOG Performance Status 0-1
- Diagnosed with China Liver Cancer Staging (CNLC) stage Ib, IIa, IIb, or IIIa hepatocellular carcinoma with specific tumor and liver function criteria
- No prior liver cancer treatment
- Tumor expected to be completely removable by surgery
- Able to provide written informed consent after full study explanation
You will not qualify if you...
- Severe heart, brain, lung, kidney, or other major organ dysfunction or serious infection preventing treatment
- History of other cancers
- Allergy to related drugs
- History of organ transplantation
- Prior liver tumor treatment including interferon
- HIV infection
- History of drug or substance abuse
- Gastrointestinal bleeding or cardiovascular/cerebrovascular events within 30 days before treatment
- Pregnant or breastfeeding women or women not using contraception
- Psychiatric disorders affecting consent or treatment
- Any other conditions that may affect enrollment or study results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
Q
Qiang Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here